DT-216

DRUG2 trials

Sponsors

Design Therapeutics, Inc.

Conditions

Friedreich Ataxia

Phase 1

Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia

CompletedNCT05285540

Design Therapeutics, Inc.Friedreich Ataxia

Start: 2022-03-11End: 2022-12-19Updated: 2023-03-28

Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia

CompletedNCT05573698

Design Therapeutics, Inc.Friedreich Ataxia

Start: 2022-09-27End: 2023-08-25Updated: 2024-02-29